<br>        Inclusion Criteria:<br><br>          -  Patients aged > 49 years and < 75 years with non-Hodgkin lymphoma (NHL), chronic<br>             lymphocytic leukemia (CLL) and multiple myeloma who are not eligible for a curative<br>             autologous transplantation or who have failed prior autologous transplantation;<br>             patients with NHL and CLL must have failed prior therapy with an alkylating agent<br>             and/or fludarabine, or be at high risk of relapse; patients with multiple myeloma must<br>             have stage II or III disease and received prior chemotherapy<br><br>          -  Patients < 50 years of age with NHL, CLL or multiple myeloma at high risk of regimen<br>             related toxicity through prior autologous transplant or through pre-existing medical<br>             conditions<br><br>          -  Patients < 75 years of age with other malignant diseases treatable by allogeneic bone<br>             marrow transplant (BMT) whom through pre-existing chronic disease affecting kidneys,<br>             liver, lungs, and heart are considered to be at high risk for regimen related toxicity<br>             using standard high dose regimens; the following diseases are the likely candidates:<br><br>               -  Myelodysplastic syndromes<br><br>               -  Myeloproliferative syndromes<br><br>               -  Acute Leukemia with < 10% blasts<br><br>               -  Amyloidosis<br><br>               -  Hodgkin's disease<br><br>               -  Renal cell carcinoma<br><br>          -  Patients with other malignancies declining standard allografts may be approved for<br>             transplant following presentation and approval by the Fred Hutchinson Cancer Research<br>             Center (FHCRC) chimerism group<br><br>          -  DONOR:<br><br>               -  Human leukocyte antigen (HLA) genotypically or phenotypically identical related<br>                  donor<br><br>               -  Donor must consent to granulocyte colony-stimulating factor (G-CSF)<br>                  administration and leukopheresis<br><br>               -  Donor must have adequate veins for leukopheresis or agree to placement of central<br>                  venous catheter (femoral, subclavian)<br><br>               -  Age < 75 years<br><br>        Exclusion Criteria:<br><br>          -  Eligible for a high-priority curative autologous transplant<br><br>          -  Patients with rapidly progressive aggressive NHL unless in minimal disease state<br><br>          -  Active central nervous system (CNS) involvement with disease<br><br>          -  Fertile men or women unwilling to use contraceptive techniques during and for 12<br>             months following treatment<br><br>          -  Females who are pregnant<br><br>          -  Patients who are human immunodeficiency virus (HIV) positive<br><br>          -  Cardiac ejection fraction < 40%<br><br>          -  Severe defects in pulmonary function testing (defects are currently categorized as<br>             mild, moderate and severe) as defined by the pulmonary consultant, or receiving<br>             supplementary continuous oxygen<br><br>          -  Total bilirubin > 2 x the upper limit of normal<br><br>          -  Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic<br>             transaminase (SGOT) 4 x the upper limit of normal<br><br>          -  Karnofsky score < 50<br><br>          -  Patients with poorly controlled hypertension<br><br>          -  Patients with renal failure are eligible, however patients with renal compromise<br>             (serum creatinine greater than 2.0) will likely have further compromise in renal<br>             function and may require hemodialysis (which may be permanent) due to the need to<br>             maintain adequate serum cyclosporine levels<br><br>          -  DONOR:<br><br>               -  Identical twin<br><br>               -  Age less than 12 years<br><br>               -  Pregnancy<br><br>               -  Infection with HIV<br><br>               -  Inability to achieve adequate venous access<br><br>               -  Known allergy to G-CSF<br><br>               -  Current serious systemic illness<br>